Sculellaria barbata polysaccharide as well as preparation method, identification method and application thereof

Abstract

The invention provides sculellaria barbata polysaccharide as well as a preparation method, an identification method and application thereof. The preparation method is simple, reaction conditions are mild, and large-scale production can be achieved; the chemical structure of the obtained high-purity sculellaria barbata polysaccharide is identified, the components of the sculellaria barbata polysaccharide are determined, and a structural basis is provided for exploring the pharmacological activity mechanism of the sculellaria barbata polysaccharide. Meanwhile, the obtained sculellaria barbata polysaccharide pure product lays a foundation for sculellaria barbata polysaccharide medicine, quality control and deep research on the structure-function relationship and the action mechanism of the sculellaria barbata polysaccharide medicine.

Description

Technical Field

[0001] The invention relates to the technical field of medicine and health food, and in particular to a Scutellaria barbata polysaccharide, a preparation method, an identification method and application thereof. Background Art

[0002] Ulcerative colitis (UC) is a chronic nonspecific inflammatory bowel disease of unknown cause. The lesions mainly affect the mucosal layer and submucosal layer of the colon and (or) rectum. Clinical manifestations include diarrhea, bloody stools with mucus, and abdominal pain. Ulcerative colitis is common in young people aged 20 to 30, and the elderly over 60 years old are also at the peak of the disease. Patients with ulcerative colitis are prone to anxiety and depression during the active period of the disease, which seriously hinders their social communication and career development. Ulcerative colitis not only threatens people's health, but also seriously affects the quality of life of patients and greatly increases the economic burden. How to diagnose and treat UC is still a major problem in the medical community.

[0003] Polysaccharides, also known as polysaccharides, are a class of bioinformatic macromolecules widely found in animals, plants and microorganisms. Natural polysaccharides play an important role in a variety of diseases, including tumors, nervous system diseases and intestinal diseases, due to their outstanding antioxidant and immunomodulatory activities. Increasing evidence shows that polysaccharides can effectively alleviate the pathological symptoms of ulcerative colitis. Therefore, searching for potential therapeutic drugs from natural polysaccharides is expected to become an effective strategy for the prevention and treatment of ulcerative colitis.

[0004] Scutelaria barbata polysaccharide is one of the components of the dried root of Scutelaria barbata D. Don, a plant of the Labiatae family. This plant is widely planted in Northeast Asia and is widely used in traditional Chinese medicine for clearing away heat and detoxification, promoting blood circulation and removing blood stasis, reducing swelling and relieving pain, and anti-cancer. Modern pharmacological studies have shown that Scutelaria barbata has multiple biological functions, including anti-tumor, antibacterial and anti-inflammatory activities. The active ingredients responsible for these biological functions are mainly flavonoids, polysaccharides, organic acids and alkaloids. At the same time, modern pharmacological studies have shown that polysaccharides, as one of the main active ingredients of Scutelaria barbata, have a wide range of pharmacological effects and have multiple beneficial effects, including anti-tumor and antioxidant activities. At present, the research on Scutelaria barbata polysaccharide mainly focuses on the optimization of its extraction process and anti-cancer activity, and there are few reports on the structure of Scutelaria barbata polysaccharide and its therapeutic effect on ulcerative colitis. Therefore, it is necessary to provide a method for extraction and structural identification to lay a foundation for the quality control of Scutelaria barbata polysaccharide and in-depth study of its anti-ulcerative colitis activity. Summary of the invention

[0005] The purpose of the present invention is to provide a Scutellaria barbata polysaccharide, a preparation method, an identification method and an application thereof, so as to solve the problems existing in the prior art.

[0006] To achieve the above object, the present invention provides the following technical solutions:

[0007] In a first aspect, the present invention discloses a method for preparing Scutellaria barbata polysaccharide, comprising the following steps:

[0008] S1 shearing: cutting the dried Scutellaria barbata peel into small segments to obtain Scutellaria barbata segments;

[0009] S2 water extraction: add the Scutellaria barbata segments into water, heat and extract, and filter to obtain the extract;

[0010] S3 alcohol precipitation: the extract is concentrated to obtain a concentrated solution, ethanol is added to the concentrated solution, and the precipitate is collected to obtain crude polysaccharides;

[0011] S4 purification: The crude polysaccharide is further deproteinized, dialyzed, concentrated and freeze-dried to purify the finished product of Scutellaria barbata polysaccharide.

[0012] Preferably, the parameters of the water extraction step are: the amount of water added is 10 times the weight of the Scutellaria barbata segment, the heating temperature is 60-100° C., and the extraction time is 1-10 hours.

[0013] Preferably, the alcohol precipitation step is:

[0014] The extract is concentrated under reduced pressure to obtain a concentrated solution, ethanol is added to a volume concentration of 80%, and the solution is allowed to stand for 10 to 28 hours, and the precipitate is collected to obtain a crude polysaccharide.

[0015] Preferably, the parameters in the purification step are: the reagent used for protein removal is a mixture of dichloromethane and n-butanol in a volume ratio of 1:4, and the concentration temperature is 70°C.

[0016] In a second aspect, the present invention provides a Scutellaria barbata polysaccharide, which is prepared by the method described above. Further, the molecular weight of the Scutellaria barbata polysaccharide is 4000-14900 Da.

[0017] In a third aspect, the present invention provides a method for identifying Scutellaria barbata polysaccharides, comprising the following steps:

[0018] (1) dissolving a polysaccharide sample of Scutellaria barbata in deionized water and performing molecular weight detection by high performance gel chromatography;

[0019] (2) dissolving a sample of Scutellaria barbata polysaccharide in deionized water and performing ultraviolet spectroscopy detection;

[0020] (3) taking a sample of Scutellaria barbata polysaccharide, drying it, pressing it into tablets, and performing infrared spectroscopy detection;

[0021] (4) taking a sample of Scutellaria barbata polysaccharide, completely hydrolyzing it with acid, and performing high performance liquid chromatography detection after derivatization of the hydrolyzate PMP;

[0022] (5) Dissolving the Scutellaria barbata polysaccharide sample in deionized water, and detecting the sugar content using the phenol-sulfuric acid method;

[0023] (6) Take a sample of Scutellaria barbata polysaccharide and dissolve it in deionized water. Use a BCA kit to detect the protein content:

[0024] (7) Take a sample of Scutellaria barbata polysaccharide and dissolve it in deionized water, and use the sulfuric acid-carbazole method to detect the uronic acid content.

[0025] The present invention also relates to the application of Scutellaria barbata polysaccharide in the preparation of anti-ulcerative colitis medicine or health care product, and evaluates the anti-ulcerative colitis activity through mouse experimental research.

[0026] Therefore, in a fourth aspect, the present invention provides the use of the Scutellaria barbata polysaccharide prepared by the preparation method as described above for the manufacture of anti-ulcerative colitis drugs or health products.

[0027] Compared with the prior art, the present invention has the following beneficial effects:

[0028] 1. The present invention adopts water extraction and alcohol precipitation method to perform preliminary separation of Scutellaria barbata polysaccharide, which has significant effect, and the preparation method is simple, the reaction conditions are mild, and large-scale production is possible;

[0029] 2. The present invention identifies the structure of the purified polysaccharide pure product, clarifies the physicochemical properties and structure of each polysaccharide component, and provides a structural basis for exploring its pharmacological activity mechanism;

[0030] 3. The Scutellaria barbata polysaccharide obtained by the present invention has well-preserved components and controllable quality. It can reduce the shortening of the colon in colitis mice, improve the infiltration of inflammatory cells in the colon tissue, and improve ulcerative colitis by regulating the expression of myeloperoxidase (MPO), inflammatory factors (including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-10 (IL-10)) and oxidative stress indicators (including malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione (GSH)), providing a basis for the application of Scutellaria barbata polysaccharide in the fields of medicine, health care products, etc.

[0031] 4. At the same time, the present invention lays a foundation for the quality control of Scutellaria barbata polysaccharide drugs and in-depth research on their structure-activity relationship and mechanism of action. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 The high performance gel permeation chromatogram and molecular weight of the Scutellaria barbata polysaccharide of the present invention;

[0033] Figure 2 The ultraviolet spectrum of the Scutellaria barbata polysaccharide of the present invention;

[0034] Figure 3 is the infrared spectrum of the Scutellaria barbata polysaccharide of the present invention;

[0035] Figure 4 The high performance liquid chromatogram of the monosaccharide composition of the Scutellaria barbata polysaccharide of the present invention;

[0036] Figure 5 is the sugar content standard curve of the Scutellaria barbata polysaccharide of the present invention;

[0037] Figure 6 is the protein standard curve of the Scutellaria barbata polysaccharide of the present invention;

[0038] Figure 7 is the uronic acid standard curve of the Scutellaria barbata polysaccharide of the present invention;

[0039] Figure 8 The flowchart of the administration of Scutellaria barbata polysaccharide to mice and its effect on the body weight and DAI score of mice;

[0040] Fig. 9 The effect of the Scutellaria barbata polysaccharide of the present invention on the colon length of mice;

[0041] Fig.10 The colon tissue of mice was observed by hematoxylin-eosin staining using the Scutellaria barbata polysaccharide of the present invention;

[0042] Fig.11 The effect of the Scutellaria barbata polysaccharide of the present invention on the expression levels of myeloperoxidase and inflammatory factors in mice;

[0043] Fig.12 The invention discloses the influence of the Scutellaria barbata polysaccharide on the expression level of oxidative stress indexes in mice. DETAILED DESCRIPTION

[0044] In order to solve the problem of insufficient research on Scutellaria barbata polysaccharide in the prior art, the present invention provides a Scutellaria barbata polysaccharide, a preparation method, an identification method and an application thereof. The preparation method of the present invention is simple, the reaction conditions are mild, and large-scale production can be achieved; and the present invention identifies the chemical structure of the obtained high-purity Scutellaria barbata polysaccharide, clarifies its components, and provides a structural basis for exploring its pharmacological activity mechanism. At the same time, the pure Scutellaria barbata polysaccharide obtained by the present invention lays a foundation for Scutellaria barbata polysaccharide drugs, quality control and in-depth research on its structure-activity relationship and mechanism of action.

[0045] The inventors use dried roots of Scutellaria barbata as raw materials, separate and obtain crude polysaccharides through water extraction and alcohol precipitation, deproteinize the extracted crude polysaccharides to obtain Scutellaria barbata polysaccharides, and systematically analyze and identify the physicochemical properties, molecular weight, monosaccharide composition and the like of the polysaccharides, and successfully obtain the structural information of the Scutellaria barbata polysaccharides, wherein the Scutellaria barbata polysaccharides are heteropolysaccharides, and the monosaccharide composition thereof is mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, arabinose and fucose.

[0046] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0047] In the description of the present invention, it should be noted that the terms "upper", "lower", "inner", "outer", "front end", "rear end", "two ends", "one end", "the other end" and the like indicating the orientation or positional relationship are only for the convenience of describing the present invention and simplifying the description, and do not indicate or imply that the device or element referred to must have a specific orientation, be constructed and operate in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first" and "second" are only used for descriptive purposes and cannot be understood as indicating or implying relative importance.

[0048] Example 1 Preparation of Scutellaria barbata polysaccharide

[0049] Scutellaria barbata polysaccharide was prepared by the following method:

[0050] S1 cutting: cut the dried Scutellaria barbata peel into small segments, wash with water, and dry to obtain Scutellaria barbata segments;

[0051] S2 water extraction: adding the Scutellaria barbata segments obtained in step S1 into water, heating for extraction, filtering, and obtaining an extract and medicinal residues;

[0052] S3 alcohol precipitation:

[0053] The extract obtained in step S2 is concentrated under reduced pressure to obtain a concentrated solution; ethanol is added to the concentrated solution until the ethanol volume concentration is 80%, the solution is allowed to stand, and the precipitate is collected to obtain a crude polysaccharide;

[0054] S4 purification:

[0055] The crude polysaccharide obtained in step S3 is subjected to protein removal, dialyzation, concentration, and freeze-drying to obtain the Scutellaria barbata polysaccharide of the present invention.

[0056] Example 2 Structural analysis of the Scutellaria barbata polysaccharide of the present invention (I) Test materials: Scutellaria barbata polysaccharide prepared according to the method of the present invention.

[0057] (II) Test methods:

[0058] 1. Molecular weight detection

[0059] Sample processing:

[0060] Weigh 2.0 mg of Scutellaria barbata polysaccharide sample into a centrifuge tube, add 1 mL of deionized water to dissolve it, and filter it with a 0.22 μm filter membrane before HPLC injection analysis.

[0061] Chromatographic conditions:

[0062] Chromatographic column: TSK gel G3000 PWXL (30cm×7.8mm, 7μm); mobile phase: 0.1M KH2PO4; flow rate: 0.5mL / min; injection volume: 20μL.

[0063] 2. Ultraviolet spectrum detection

[0064] 3.0 mg of Scutellaria barbata polysaccharide sample was weighed into a centrifuge tube, 3 mL of deionized water was added for dissolution, and full wavelength scanning was performed in the range of 200-400 nm using a Spectrum SP-756P UV-visible spectrophotometer.

[0065] 3. Infrared spectrum detection

[0066] 2.0 mg of the dried test material was ground with KBr, pressed into pellets, and analyzed by Shimadzu IRAffinity-1 at 4000–400 cm -1 Scan within the range.

[0067] 4. Monosaccharide composition analysis

[0068] Sample processing:

[0069] Accurately weigh 4.0 mg of Scutellaria barbata polysaccharide sample into a stoppered test tube, add 2 mL of 2M trifluoroacetic acid (TFA), and place in an oil bath at 120°C for 6 hours for hydrolysis. Cool to room temperature, repeatedly add methanol to dryness, remove TFA, dissolve in deionized water to 1 mL, centrifuge, take 100 μL of sample solution, add 100 μL of 0.3M NaOH solution, then add 100 μL of 0.5M PMP methanol solution, mix well, react in a 70°C water bath for 30 minutes, cool, and add 105 μL of 0.3M HCl.

[0070] The solution was neutralized, deionized water was added to 1 mL, and then an equal volume of chloroform solution was added. The solution was shaken vigorously and centrifuged to remove the chloroform phase. This extraction was repeated twice. The aqueous phase was filtered with a 0.22 μm filter membrane and then used for HPLC injection analysis.

[0071] Chromatographic conditions:

[0072] Chromatographic column: Kromasil 100-5-C18, 4.6×250 mm, 5 μm; mobile phase: 0.1 M phosphate (pH=6.9) buffer-acetonitrile (v / v is 83:17); detection wavelength: 250 nm; flow rate: 0.8 mL / min; injection volume: 20 μL.

[0073] 5. Sugar content detection

[0074] Take 100 mg of glucose standard and dilute to 100 mL (1 mg / mL), and dilute in test tubes to 0.01, 0.02, 0.05, 0.08, 0.1, 0.2, 0.3, 0.4 mg / mL. Weigh 10 mg of polysaccharide sample and dilute to 100 mL. Pipette 400 μL of sample, add 200 μL of 5% phenol and 1 mL of concentrated sulfuric acid, vortex, and scan at 490 nm using a Spectrum SP-756P UV-visible spectrophotometer. Treat the test sample as above. Prepare a standard curve based on the concentration of the standard and the absorbance to determine the sugar content of the sample.

[0075] 6. Protein content detection

[0076] The detection was performed using a BCA protein kit.

[0077] 7. Uric acid content detection

[0078] Preparation of standard solution:

[0079] Preparation of reference solution: Accurately weigh 10 mg of dry galacturonic acid, dissolve it with an appropriate amount of distilled water, and make up to volume in a 100 mL volumetric flask to prepare a 100 μg / mL reference solution.

[0080] Preparation of test solution:

[0081] Accurately weigh 20 mg of polysaccharide, add distilled water to dissolve, and make up to volume in a 100 mL volumetric flask to prepare a solution with a concentration of 200 μg / mL.

[0082] Preparation of sodium tetraborate-sulfuric acid solution

[0083] Accurately weigh 478 mg of sodium tetraborate and dissolve it in 100 mL of concentrated sulfuric acid for later use.

[0084] Preparation of carbazole solution:

[0085] Accurately weigh 15 mg of carbazole and dissolve it in 10 mL of anhydrous ethanol to prepare a 0.15% carbazole solution for later use.

[0086] Pipette 1 mL of the test solution respectively and place it in a 10 mL stoppered test tube, add 5 mL of sodium tetraborate-sulfuric acid solution in an ice-water bath in a foam box, mix well with a vortex mixer, heat in a 100°C oil bath for 20 min, take out and immediately cool to room temperature, add 0.2 mL of 0.15% carbazole solution, vortex, and keep at room temperature for 2 h.

[0087] Preparation of standard curve:

[0088] Accurately pipette 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1 mL of the reference solution into 10 mL stoppered test tubes, add water to each tube to 1 mL, add 5 mL of sodium tetraborate-sulfuric acid solution in an ice water bath, cool to room temperature immediately after taking out, add 0.2 mL of 0.15% carbazole solution, vortex, keep at room temperature for 2 h, use 1 mL of distilled water blank reagent as a reference solution, and measure the absorbance at the optimal measurement wavelength of 523 nm.

[0089] (III) Test results:

[0090] 1. Structural analysis of polysaccharides from Scutellaria barbata

[0091] (1) Molecular weight detection

[0092] like Figure 1 As shown in the liquid chromatography, it can be seen that the molecular weight range of the Scutellaria barbata polysaccharide of the present invention is 4000-14900Da.

[0093] (2) Ultraviolet spectrum analysis

[0094] like Figure 2 As shown, it can be seen from the ultraviolet spectrum that the Scutellaria barbata polysaccharide of the present invention contains the ultraviolet characteristic absorption peak of polysaccharide, and the small peak at 280nm represents that the Scutellaria barbata polysaccharide of the present invention contains trace protein.

[0095] (3) Infrared spectroscopy analysis

[0096] like Figure 3 As shown, it can be seen from the infrared spectrum that the Scutellaria barbata polysaccharide of the present invention contains characteristic absorption peaks of polysaccharides.

[0097] (4) Monosaccharide composition analysis

[0098] like Figure 4 As shown, it can be seen from the HPLC spectrum that the Scutellaria barbata polysaccharide of the present invention contains mannose, rhamnose, glucuronic acid, galacturonic acid, glucose, arabinose and fucose. (Chromatographic peak sequence: 1: mannose, 2: rhamnose, 3: glucuronic acid, 4: galacturonic acid, 5: glucose, 6: galactose, 7: xylose, 8: arabinose, 9: fucose; SBP1 refers to the Scutellaria barbata polysaccharide of the present invention)

[0099] (5) Sugar content detection, protein content and uronic acid content

[0100] like Figure 5 Shown is the standard curve of sugar content. Figure 6 Shown is the standard curve of protein content. Figure 7 The standard curve of uronic acid content is shown. Substituting into the standard curve, the sugar content of the Scutellaria barbata polysaccharide of the present invention is 83%, the protein content is 37.8%, and the uronic acid content is 4.1%.

[0101]

[0102]

[0103] Example 4 Study on the anti-inflammatory and antioxidant effects of Scutellaria barbata polysaccharide of the present invention on colitis mice

[0104] (I) Test materials: Scutellaria barbata polysaccharide of the present invention.

[0105] (II) Experimental subjects: C57BL / 6J male mice (provided by Zhuhai Baishitong Biotechnology Co., Ltd.).

[0106] (III) Test methods:

[0107] 1. Experimental design and grouping:

[0108] The present invention adopts a DSS-induced mouse model, and sets a blank group (NC), a modeling group (DSS), a positive drug mesalazine group (5-ASA) and a Scutellaria barbata polysaccharide administration group (SBP1), wherein the concentration of DSS is 2% (w / v), and the dosage of mesalazine and the Scutellaria barbata polysaccharide of the present invention is 200 mg / kg.

[0109] 2. DAI Rating

[0110] To determine the DAI, fecal characteristics, diarrhea, and rectal bleeding were recorded for all mice, and the body weight of each mouse was recorded daily.

[0111] 3. Changes in mouse colon length

[0112] After the experiment, the mice were fed freely for 24 h before anesthesia and euthanasia. During the surgery, the cecum and colon were cut together to maintain the integrity of the colon. The length of the colon was measured using a ruler, and photos of the colon were taken, which were then stored at -80 °C.

[0113] 4. Hematoxylin-eosin Staining

[0114] The colon tissues were fixed with 10% formaldehyde solution and then dehydrated with gradient ethanol. Subsequently, the tissues were embedded in paraffin and stained with hematoxylin-eosin. The structural differences of the colon tissues of the four groups of mice were then examined under a microscope.

[0115] 5. Serum and Colon Biochemical Evaluation

[0116] The levels of inflammatory factors (TNF-α, IL-1β, and IL-6) in the blood of mice were measured using ELISA kits. In addition, the expression level of MPO and the level of antioxidant system (SOD, GSH, and MDA) in the colon tissue of mice were determined according to the established protocol.

[0117] (IV) Experimental results

[0118] like Figure 8-12 As shown in the figure, after DSS treatment, the body weight, DAI score and colon length of mice decreased significantly (P < 0.001), hematoxylin-eosin staining showed obvious colon tissue damage, the expression levels of MPO and pro-inflammatory factors (TNF-α and IL-1β) increased significantly (P < 0.001), the expression level of anti-inflammatory factor IL-10 decreased significantly (P < 0.001), the expression level of MDA increased significantly (P < 0.001), and the expression levels of SOD and GSH decreased significantly (P < 0.001), indicating that the DSS-induced colitis model in mice was successfully established. After being treated with the Scutellaria barbata polysaccharide of the present invention, the phenomenon of weight loss in colitis mice is significantly improved (P<0.001), the weight loss and colon shortening of mice are improved (P<0.001), the DAI score is reduced (P<0.001), the colon tissue damage is reversed, the expression levels of MPO and pro-inflammatory factors (TNF-α and IL-1β) are significantly reduced (P<0.05, P<0.001, P<0.001), the expression level of anti-inflammatory factor IL-10 is significantly increased (P<0.01), the expression level of MDA is significantly reduced (P<0.001), and the expression levels of SOD and GSH are significantly increased (P<0.01, P<0.001), indicating that the Scutellaria barbata polysaccharide of the present invention can treat colitis by regulating the expression of MPO, reducing the level of pro-inflammatory factors, increasing the level of anti-inflammatory factors, and improving oxidative stress to prevent oxidative damage. In addition, the Scutellaria barbata polysaccharide of the present invention has no significant difference with the positive drug mesalazine in the ability to regulate DAI score, MPO expression level, inflammatory factor expression level and improve oxidative stress, and the Scutellaria barbata polysaccharide of the present invention is significantly superior to mesalazine in the ability to reduce weight loss in mice (P < 0.01).

[0119] The matters not described in detail in the present invention are all known technologies to those skilled in the art.

[0120] Finally, it should be noted that the above specific implementation methods are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified and replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.

Claims

1. A method for preparing Scutellaria barbata polysaccharide, characterized in that: The method comprises the following steps: S1 shearing: cutting the dried Scutellaria barbata peel into small segments to obtain Scutellaria barbata segments; S2 water extraction: add the Scutellaria barbata segments into water, heat and extract, and filter to obtain the extract; S3 alcohol precipitation: the extract is concentrated to obtain a concentrated solution, ethanol is added to the concentrated solution, and the precipitate is collected to obtain crude polysaccharides; S4 purification: The crude polysaccharide is further deproteinized, dialyzed, concentrated and freeze-dried to purify the finished product of Scutellaria barbata polysaccharide.

2. The method according to claim 1, characterized in that The parameters of the water extraction step are: the amount of water added is 10 times the weight of the Scutellaria barbata segment, the heating temperature is 60-100°C, and the extraction time is 1-10 h.

3. The method according to claim 1, characterized in that The alcohol precipitation step is: The extract was concentrated under reduced pressure to obtain a concentrated solution, ethanol was added to a volume concentration of 80%, and the solution was allowed to stand for 10 to 28 hours, and the precipitate was collected to obtain a crude polysaccharide.

4. The method according to claim 1, characterized in that The parameters in the purification step are as follows: the volume ratio of the reagent used for protein removal is a mixture of dichloromethane and n-butanol in a ratio of 1:4, and the concentration temperature is 70°C.

5. A Scutellaria barbata polysaccharide, characterized in that: The Scutellaria barbata polysaccharide is prepared by the method according to any one of claims 1 to 4.

6. The Scutellaria barbata polysaccharide according to claim 5, characterized in that The molecular weight of the Scutellaria barbata polysaccharide is 4000-14900Da.

7. A method for identifying polysaccharides from Scutellaria barbata, characterized in that: The method comprises the following steps: (1) Dissolve the Scutellaria barbata polysaccharide sample in deionized water and perform molecular weight detection using high performance gel chromatography; (2) Dissolve the Scutellaria barbata polysaccharide sample in deionized water and perform UV spectroscopy detection; (3) taking a sample of Scutellaria barbata polysaccharide, drying it, pressing it into tablets, and performing infrared spectroscopy detection; (4) taking a sample of Scutellaria barbata polysaccharide, completely hydrolyzing it with acid, and then derivatizing the hydrolyzate PMP and performing high performance liquid chromatography detection; (5) Dissolve the Scutellaria barbata polysaccharide sample in deionized water and detect the sugar content using the phenol-sulfuric acid method; (6) Dissolve the Scutellaria barbata polysaccharide sample in deionized water and use the BCA kit to detect the protein content: (7) Take the Scutellaria barbata polysaccharide sample and dissolve it in deionized water, and use the sulfuric acid-carbazole method to detect the uronic acid content.

8. Use of the Scutellaria barbata polysaccharide prepared by the preparation method according to any one of claims 1 to 4 or the Scutellaria barbata polysaccharide according to any one of claims 5 to 6 in the manufacture of an anti-ulcerative colitis drug or health product.

Images